350 related articles for article (PubMed ID: 19628292)
21. Gemcitabine-cisplatin given on day 1 every 3 weeks in advanced non-small cell lung cancer.
Karacetin D; Incekara O
J BUON; 2006; 11(2):181-4. PubMed ID: 17318968
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
Park K; Cho EK; Bello M; Ahn MJ; Thongprasert S; Song EK; Soldatenkova V; Depenbrock H; Puri T; Orlando M
Cancer Res Treat; 2017 Oct; 49(4):937-946. PubMed ID: 28111429
[TBL] [Abstract][Full Text] [Related]
24. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.
Manegold C; van Zandwijk N; Szczesna A; Zatloukal P; Au JSK; Blasinska-Morawiec M; Serwatowski P; Krzakowski M; Jassem J; Tan EH; Benner RJ; Ingrosso A; Meech SJ; Readett D; Thatcher N
Ann Oncol; 2012 Jan; 23(1):72-77. PubMed ID: 21464154
[TBL] [Abstract][Full Text] [Related]
25. Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling.
Huisman C; Giaccone G; van Groeningen CJ; Sutedja G; Postmus PE; Smit EF
Lung Cancer; 2001; 33(2-3):267-75. PubMed ID: 11551422
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
Perng RP; Chen YM; Ming-Liu J; Tsai CM; Lin WC; Yang KY; Whang-Peng J
J Clin Oncol; 1997 May; 15(5):2097-102. PubMed ID: 9164223
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
Gatzemeier U; Groth G; Butts C; Van Zandwijk N; Shepherd F; Ardizzoni A; Barton C; Ghahramani P; Hirsh V
Ann Oncol; 2004 Jan; 15(1):19-27. PubMed ID: 14679114
[TBL] [Abstract][Full Text] [Related]
28. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer.
Rosell R; Tonato M; Sandler A
Semin Oncol; 1998 Aug; 25(4 Suppl 9):27-34. PubMed ID: 9728582
[TBL] [Abstract][Full Text] [Related]
29. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.
Soto Parra H; Cavina R; Latteri F; Sala A; Dambrosio M; Antonelli G; Morenghi E; Alloisio M; Ravasi G; Santoro A
Ann Oncol; 2002 Jul; 13(7):1080-6. PubMed ID: 12176787
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.
Morabito A; Gebbia V; Di Maio M; Cinieri S; Viganò MG; Bianco R; Barbera S; Cavanna L; De Marinis F; Montesarchio V; Costanzo R; Sandomenico C; Montanino A; Mancuso G; Russo P; Nacci A; Giordano P; Daniele G; Piccirillo MC; Rocco G; Gridelli C; Gallo C; Perrone F
Lung Cancer; 2013 Jul; 81(1):77-83. PubMed ID: 23643177
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Crinò L; Scagliotti G; Marangolo M; Figoli F; Clerici M; De Marinis F; Salvati F; Cruciani G; Dogliotti L; Pucci F; Paccagnella A; Adamo V; Altavilla G; Incoronato P; Trippetti M; Mosconi AM; Santucci A; Sorbolini S; Oliva C; Tonato M
J Clin Oncol; 1997 Jan; 15(1):297-303. PubMed ID: 8996156
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Pujol JL; Breton JL; Gervais R; Rebattu P; Depierre A; Morère JF; Milleron B; Debieuvre D; Castéra D; Souquet PJ; Moro-Sibilot D; Lemarié E; Kessler R; Janicot H; Braun D; Spaeth D; Quantin X; Clary C
Ann Oncol; 2005 Apr; 16(4):602-10. PubMed ID: 15741225
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
Comella P; Frasci G; Panza N; Manzione L; Lorusso V; Di Rienzo G; Cioffi R; De Cataldis G; Maiorino L; Bilancia D; Nicolella G; Natale M; Carpagnano F; Pacilio C; De Lena M; Bianco A; Comella G
J Clin Oncol; 1999 May; 17(5):1526-34. PubMed ID: 10334540
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.
Laack E; Dickgreber N; Müller T; Knuth A; Benk J; Lorenz C; Gieseler F; Dürk H; Engel-Riedel W; Dalhoff K; Kortsik C; Graeven U; Burk M; Dierlamm T; Welte T; Burkholder I; Edler L; Hossfeld DK;
J Clin Oncol; 2004 Jun; 22(12):2348-56. PubMed ID: 15197195
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
Hsu C; Kuo SH; Hu FC; Cheng AL; Shih JY; Yu CJ; Lin CC; Huang TC; Yang PC; Yang CH
Lung Cancer; 2008 Dec; 62(3):334-43. PubMed ID: 18450322
[TBL] [Abstract][Full Text] [Related]
37. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
Smit EF; van Meerbeeck JP; Lianes P; Debruyne C; Legrand C; Schramel F; Smit H; Gaafar R; Biesma B; Manegold C; Neymark N; Giaccone G;
J Clin Oncol; 2003 Nov; 21(21):3909-17. PubMed ID: 14581415
[TBL] [Abstract][Full Text] [Related]
38. [Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment].
Xiong JP; Zhang L; Zhong LX; Qiu F; Guo YL; Lian HY; Luo H
Ai Zheng; 2006 Aug; 25(8):995-8. PubMed ID: 16965681
[TBL] [Abstract][Full Text] [Related]
39. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
Xiong JP; Feng M; Qiu F; Xu J; Tao QS; Zhang L; Xiang XJ; Zhong LX; Yu F; Ma XT; Gong WY
Lung Cancer; 2008 May; 60(2):208-14. PubMed ID: 18023915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
